Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Buhl Krone Holding ApS | 20,42 | 20,42 | 2025-12-23 |
| Claus Frisenberg Pedersen | 11,68 | 11,68 | 2023-01-18 |
| IPO Nordic Fund A/S | 7,52 | 7,52 | 2025-12-23 |
| Smerud Medical Research International AS | 6,72 | 6,72 | 2025-12-23 |
| Rutger Arnhult | 4,93 | 4,93 | 2025-12-23 |
| Nels Holding Aps | 4,01 | 4,01 | 2026-01-19 |
| Lh|Lh Invest Aps | 2,67 | 2,67 | 2025-12-23 |
| Sorgenfri Nr. 1 A/S | 2,58 | 2,58 | 2026-01-19 |
| Karsgaard Holding Ostervra Aps | 2,41 | 2,41 | 2025-12-23 |
| Xiaoliang Wu | 2,17 | 2,17 | 2025-12-23 |
2026-05-27 Annual General Meeting 2025
2026-05-30 Interim Report 2026-Q1
